Objectives: To compare the success of two controlled ovarian hyperstimulation protocols; rFSH + hp-hMG with only rFSH in the GnRH antagonist protocol in diminished ovarian reserve under 35 years of age. Material and methods: Data from January 2015 to June 2019 were abstracted from the hospital records of IVF Clinic. The women younger than 35 years of age who were diagnosed as diminished ovarian reserve and underwent standard GnRH antagonist protocol were included. Patients in Group-1 underwent controlled ovarian stimulation with rFSH alone and Group-2 with rFSH in combination with hp-hMG. Patients in both groups were divided into three subgroups according to their antral follicle count at Day 3: < 4 (a), 4–6 (b), and 7–10 (c). Demograph...
Background: Gonadotrophin-releasing hormone (GnRH) antagonists can be used to prevent a luteinizing ...
In approximately 12-14% of young normogonadotrophic women treated with a depot GnRH agonist long pro...
In approximately 12-14% of young normogonadotrophic women treated with a depot GnRH agonist long pro...
Study question: Does the addition of exogenous LH to an IVF/ICSI stimulation protocol with recombina...
Background: Some studies have suggested that the suppression of endogenous LH secretion does not see...
Background: The question of the dominance of recombinant FSH(r FSH) for controlled ovarian stimulati...
Luteinizing hormone (LH) is essential for normal follicular development and oocyte maturation. In pa...
Background: Objective of current study was to assess the effect of GnRH antagonist on follicular dev...
Background: In 3c 12-14% of young normogonadotrophic women treated with a depot GnRH agonist long p...
Background: In ∼ 12-14% of young normogonadotrophic women treated with a depot GnRH agonist long pro...
AbstractObjectiveThe present retrospective and controlled comparative study was designed to evaluate...
Copyright © 2015 Martin Stimpfel et al.This is an open access article distributed under the Creative...
Background: The high prevalence of infertility has made it a major healthcare problem in the present...
The reports on how to stimulate the ovaries for oocyte retrieval in good prognosis patients are cont...
In approximately 12-14% of young normogonadotrophic women treated with a depot GnRH agonist long pro...
Background: Gonadotrophin-releasing hormone (GnRH) antagonists can be used to prevent a luteinizing ...
In approximately 12-14% of young normogonadotrophic women treated with a depot GnRH agonist long pro...
In approximately 12-14% of young normogonadotrophic women treated with a depot GnRH agonist long pro...
Study question: Does the addition of exogenous LH to an IVF/ICSI stimulation protocol with recombina...
Background: Some studies have suggested that the suppression of endogenous LH secretion does not see...
Background: The question of the dominance of recombinant FSH(r FSH) for controlled ovarian stimulati...
Luteinizing hormone (LH) is essential for normal follicular development and oocyte maturation. In pa...
Background: Objective of current study was to assess the effect of GnRH antagonist on follicular dev...
Background: In 3c 12-14% of young normogonadotrophic women treated with a depot GnRH agonist long p...
Background: In ∼ 12-14% of young normogonadotrophic women treated with a depot GnRH agonist long pro...
AbstractObjectiveThe present retrospective and controlled comparative study was designed to evaluate...
Copyright © 2015 Martin Stimpfel et al.This is an open access article distributed under the Creative...
Background: The high prevalence of infertility has made it a major healthcare problem in the present...
The reports on how to stimulate the ovaries for oocyte retrieval in good prognosis patients are cont...
In approximately 12-14% of young normogonadotrophic women treated with a depot GnRH agonist long pro...
Background: Gonadotrophin-releasing hormone (GnRH) antagonists can be used to prevent a luteinizing ...
In approximately 12-14% of young normogonadotrophic women treated with a depot GnRH agonist long pro...
In approximately 12-14% of young normogonadotrophic women treated with a depot GnRH agonist long pro...